Very low-dose radiation eased myeloma bone pain in a small trial
A seven-institution phase two trial presented for the Boston oncology meeting tested a small radiation dose for painful myeloma bone lesions without urgent complications. About three in five evaluable patients reported a pain response within four weeks, rising to about four in five by six months. Nineteen percent needed another course at the same site. The trial had no comparison arm, so it cannot establish superiority over standard treatment.
Science··Morning
A small radiation course targeted painful bone lesions
A phase 2 trial presented for the Boston radiation oncology meeting tested very low-dose radiation in people with painful bone lesions from multiple myeloma. This cancer begins in plasma cells in bone marrow and can damage bone. The seven-institution study excluded urgent problems such as spinal cord compression or a fracture of a long bone. Patients initially received a total of four gray in one or two sessions. AuntMinnie independently reported the same presentation and its four-week pain-response headline; the conference announcement supplies the treatment and eligibility details.[1], [2]
Pain relief rose between one and six months
Among evaluable patients, about three in five had a pain response within four weeks and about four in five by six months. Pain was assessed using patient reports alongside oral morphine-equivalent medicine use. For those with insufficient relief after the first month, more radiation was permitted. A second course was needed by 19% at the same site, at a median of roughly ten weeks after the initial treatment. The measured response therefore includes a treatment pathway in which some people had additional radiation rather than relying solely on the first small dose.[1]
A comparison arm is still missing
The reported adverse effects were mild: four patients had fatigue and one had a skin change. Even so, this small single-arm trial cannot show that the regimen works better than usual care or another radiation schedule. It also cannot be extended to patients with the urgent complications that the study deliberately excluded. Bone pain can greatly reduce quality of life for people with myeloma, which makes a short course worth investigating, but the meeting result has not yet appeared in a journal. A direct comparison would be needed to judge how much of the observed relief belongs to this dose and schedule.[1]
